Patient Considerations in R/R Mantle Cell Lymphoma Treatment: Anita Kumar, MD

Video

The Regional Care Network Medical Site Director at Memorial Sloan Kettering Cancer Center Basking Ridge discussed patient factors to consider when selecting treatment in R/R MCL.

This content originally appeared on our sister site, OncLive.

OncLive spoke with Anita Kumar, MD, medical oncologist, Regional Care Network Medical Site Director, MSK Basking Ridge, Memorial Sloan Kettering Cancer Center, about patient factors to consider when selecting treatment in relapsed/refractory mantle cell lymphoma (MCL).

Kumar discussed several patient considerations that should be accounted for at the time of treatment initiation, including age, overall fitness, and existing comorbidities. Patient goals with therapies should also be considered, Kumar added. Some patients prefer to receive well-tolerated therapies to maximize quality of life, whereas others prefer to treat their MCL aggressively with all available options, Kumar said. Moreover, patient preference could determine whether they should be treated in a community setting vs an academic setting, Kumar added.

Other considerations include whether the patient is eligible for CAR T-cell therapy, autologous stem cell transplant, and allogeneic stem cell transplant, Kumar says. Regarding the latter, donor availability then becomes an additional factor to consider, Kumar concluded.

Related Videos
Zheng-Yi Chen, DPhil, on International Collaboration on Clinical Trials
Janice Chen, PhD, the cofounder and chief technology officer of Mammoth Biosciences
Sekar Kethiresan, MD, on Following up VERVE-101 With Next-Generation Editing Therapies
Maria Escolar, MD, the chief medical officer of Forge Biologics
Leigh Ramos-Platt, MD, on Allowing Access and Ensuring Preparation for Gene Therapies
John Murphy, PhD, the chief scientific officer of Arbor Biotechnologies
Erika Fullwood Augustine, MD, MS, the associate chief science officer of the Kennedy Krieger Institute
Maria Escolar, MD, the chief medical officer of Forge Biologics
Casey Maguire, PhD, associate professor of neurology and associate investigator of neurology, Harvard Medical School
Faraz Ali, MBA, the chief executive officer of Tenaya Therapeutics
© 2024 MJH Life Sciences

All rights reserved.